CYTK · Cytokinetics, Incorporated

Summary

Cytokinetics, Incorporated announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.

Key takeaways

• European Commission approved MYQORZO® (aficamten)
• Approved dosages: 5 mg, 10 mg, 15 mg, 20 mg tablets
• Indication: symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy
• Patient population: adult patients
• Mechanism: allosteric and reversible inhibitor of cardiac myosin motor activity